"Trastuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
Descriptor ID |
D000068878
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.875 D12.776.124.790.651.114.224.060.875 D12.776.377.715.548.114.224.200.875
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trastuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Trastuzumab [D12.776.124.486.485.114.224.060.875]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Trastuzumab [D12.776.124.790.651.114.224.060.875]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Trastuzumab [D12.776.377.715.548.114.224.200.875]
Below are MeSH descriptors whose meaning is more specific than "Trastuzumab".
This graph shows the total number of publications written about "Trastuzumab" by people in this website by year, and whether "Trastuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 2 | 2 |
2003 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 0 | 4 | 4 |
2006 | 0 | 2 | 2 |
2007 | 0 | 2 | 2 |
2009 | 0 | 1 | 1 |
2010 | 0 | 3 | 3 |
2011 | 0 | 6 | 6 |
2012 | 0 | 2 | 2 |
2013 | 0 | 1 | 1 |
2014 | 1 | 1 | 2 |
2015 | 0 | 4 | 4 |
2017 | 0 | 4 | 4 |
2018 | 2 | 1 | 3 |
2019 | 2 | 5 | 7 |
2020 | 1 | 1 | 2 |
2021 | 2 | 2 | 4 |
2023 | 0 | 4 | 4 |
2024 | 1 | 0 | 1 |
2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trastuzumab" by people in Profiles.
-
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Res Treat. 2025 Jul; 212(1):57-69.
-
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response. JCO Precis Oncol. 2025 Apr; 9:e2400546.
-
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). Breast. 2025 Jun; 81:104432.
-
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. J Clin Oncol. 2025 Apr 10; 43(11):1348-1357.
-
HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025; 1464:495-525.
-
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb; 21(3):303-311.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 11 25; 15(1):10213.
-
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Res Treat. 2025 Feb; 210(1):191-203.
-
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4856-4865.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.